Literature DB >> 32169222

Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines.

P Bossi1, A Antonuzzo2, N I Cherny3, O Rosengarten3, S Pernot4, F Trippa5, U Schuler6, A Snegovoy7, K Jordan8, C I Ripamonti9.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32169222     DOI: 10.1093/annonc/mdy145

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms.

Authors:  Arjun Gupta; Leonce Nshuti; Udhayvir S Grewal; Ramy Sedhom; Devon K Check; Helen M Parsons; Anne H Blaes; Beth A Virnig; Maryam B Lustberg; Ishwaria M Subbiah; Ryan D Nipp; Sydney M Dy; Stacie B Dusetzina
Journal:  JCO Oncol Pract       Date:  2021-09-24

Review 2.  Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.

Authors:  Domenica Lorusso; Jesús García-Donas; Jalid Sehouli; Florence Joly
Journal:  Target Oncol       Date:  2020-06       Impact factor: 4.493

3.  The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.

Authors:  Helena Harder; Valerie M Shilling; Shirley F May; David Cella; Peter Schmid; Lesley J Fallowfield
Journal:  Breast Cancer Res Treat       Date:  2020-07-27       Impact factor: 4.872

4.  Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Brian W Labadie; David S Morris; Alan H Bryce; Robert Given; Jingsong Zhang; Wassim Abida; Simon Chowdhury; Akash Patnaik
Journal:  Cancer Manag Res       Date:  2022-02-17       Impact factor: 3.989

5.  Impact of Open Dialogue about Complementary Alternative Medicine-A Phase II Randomized Controlled Trial.

Authors:  Mette Stie; Charlotte Delmar; Birgitte Nørgaard; Lars Henrik Jensen
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.